MoonLake ImmunotherapeuticsMLTX
| Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
---|
Research and development | - | - | 42 | 32 |
---|
General and administrative | - | 5 | 23 | 22 |
---|
Total operating expenses | - | - | 65 | 54 |
---|
Operating loss | -105,755 | -4,570,345 | -65,061,417 | -54,123,096 |
---|
Other income (expense), net | - | - | 591,732 | - |
---|
Other income, net | - | - | - | 10 |
---|
Loss before income tax | - | - | -64,469,685 | -43,984,729 |
---|
Income tax expense | - | - | 36,366 | 94,388 |
---|
Net loss | - | - | -64,506,051 | -44,079,117 |
---|
Of which: net loss attributable to controlling interests shareholders | -90,838 | -4,542,654 | -49,973,249 | -36,007,260 |
---|
Net Income (Loss) Attributable to Noncontrolling Interest | - | -4,542,654 | -14,532,802 | -8,071,857 |
---|
Net unrealized gain on marketable securities and short-term investments | - | - | 390,753 | 2 |
---|
Actuarial income (loss) on employee benefit plans | - | - | 269,893 | -336,579 |
---|
Other comprehensive income | - | - | 660,646 | 2 |
---|
Comprehensive loss | - | - | -63,845,405 | -42,085,595 |
---|
Comprehensive loss attributable to controlling interests shareholders | - | - | -49,437,461 | -34,511,723 |
---|
Comprehensive loss attributable to noncontrolling interests | - | - | -14,407,944 | -7,573,872 |
---|
Earnings Per Share, Diluted | - | - | -1.7 | -0.73 |
---|
Earnings Per Share, Basic | - | - | -1.7 | -0.73 |
---|